{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T01:04:03Z","timestamp":1784423043128,"version":"3.55.0"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T00:00:00Z","timestamp":1639958400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.yebeh.2021.108517","type":"journal-article","created":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T06:57:33Z","timestamp":1642661853000},"page":"108517","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["The importance of drug titration in the management of patients with epilepsy"],"prefix":"10.1016","volume":"128","author":[{"given":"Lawrence G.","family":"Seiden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory S.","family":"Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.yebeh.2021.108517_b0005","doi-asserted-by":"crossref","first-page":"226","DOI":"10.5694\/mja17.00951","article-title":"The management of epilepsy in children and adults","volume":"208","author":"Perucca","year":"2018","journal-title":"Med J Aust"},{"key":"10.1016\/j.yebeh.2021.108517_b0010","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.seizure.2016.11.022","article-title":"Drug development for refractory epilepsy: the past 25 years and beyond","volume":"44","author":"Golyala","year":"2017","journal-title":"Seizure"},{"issue":"7","key":"10.1016\/j.yebeh.2021.108517_b0015","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/j.1528-1167.2006.00585.x","article-title":"ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes","volume":"47","author":"Glauser","year":"2006","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.yebeh.2021.108517_b0020","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/j.1528-1167.2011.03355.x","article-title":"Revising the \u201cRule of Three\u201d for inferring seizure freedom","volume":"53","author":"Brandon Westover","year":"2012","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.yebeh.2021.108517_b0025","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/epi.12074","article-title":"Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes","volume":"54","author":"Glauser","year":"2013","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.yebeh.2021.108517_b0030","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/jamaneurol.2017.3949","article-title":"Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study","volume":"75","author":"Chen","year":"2018","journal-title":"JAMA Neurol"},{"issue":"5","key":"10.1016\/j.yebeh.2021.108517_b0035","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S1474-4422(11)70047-3","article-title":"The pharmacological treatment of epilepsy in adults","volume":"10","author":"Perucca","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2021.108517_b0040","unstructured":"XCOPRI\u00ae (cenobamate tablets), for oral use, CV [prescribing information]. Paramus, NJ: SK Life Science, Inc.; April, 2021."},{"key":"10.1016\/j.yebeh.2021.108517_b0045","unstructured":"VIMPAT\u00ae (lacosamide) film coated tablet, for oral use, CV. VIMPAT\u00ae (lacosamide) injection, for intravenous use, CV. VIMPAT\u00ae (lacosamide) oral solution, CV [prescribing information]. Smyrna, GA: UCB, Inc.; November, 2020."},{"key":"10.1016\/j.yebeh.2021.108517_b0050","unstructured":"APTIOM\u00ae (eslicarbazepine acetate) tablets, for oral use [prescribing information]. Marlborough, MA: Sunovion Pharmaceuticals Inc.; March, 2019."},{"key":"10.1016\/j.yebeh.2021.108517_b0055","unstructured":"LAMICTAL\u00ae (lamotrigine) tablets, for oral use. LAMICTAL (lamotrigine) chewable dispersible tablets, for oral use. LAMICTAL ODT (lamotrigine) orally disintegrating tablets, for oral use [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; October, 2020."},{"key":"10.1016\/j.yebeh.2021.108517_b0060","unstructured":"KEPPRA\u00ae (levetiracetam). 250 mg, 500 mg, 750 mg, and 1000 mg tablets. 100 mg\/mL oral solution [prescribing information]. Smyrna, GA: UCB, Inc.; October, 2019."},{"key":"10.1016\/j.yebeh.2021.108517_b0065","unstructured":"FYCOMPA\u00ae (perampanel) tablets, for oral use, CIII. FYCOMPA\u00ae (perampanel) oral suspension, CIII [prescribing information]. Woodcliff Lake, NJ: Eisai Inc.; September, 2021."},{"key":"10.1016\/j.yebeh.2021.108517_b0070","unstructured":"TOPAMAX\u00ae (topiramate) TABLETS, for oral use. TOPAMAX\u00ae (topiramate capsules) SPRINKLE CAPSULES, for oral use [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; June, 2020."},{"issue":"9","key":"10.1016\/j.yebeh.2021.108517_b0075","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S1474-4422(12)70153-9","article-title":"Adverse effects of antiepileptic drugs","volume":"11","author":"Perucca","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2021.108517_b0080","series-title":"Epilepsy and the interictal state: co-morbidities and quality of life","first-page":"120","article-title":"Minimizing the adverse effects of epilepsy therapies: principles and practice","author":"St. Louis","year":"2015"},{"issue":"7","key":"10.1016\/j.yebeh.2021.108517_b0085","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1053\/seiz.2000.0442","article-title":"Epilepsy after the first drug fails: substitution or add-on?","volume":"9","author":"Kwan","year":"2000","journal-title":"Seizure"},{"issue":"6","key":"10.1016\/j.yebeh.2021.108517_b0090","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/da.21952","article-title":"The association between antidepressant dosage titration and medication adherence among patients with depression","volume":"29","author":"Wu","year":"2012","journal-title":"Depress Anxiety"},{"key":"10.1016\/j.yebeh.2021.108517_b0095","doi-asserted-by":"crossref","first-page":"107844","DOI":"10.1016\/j.yebeh.2021.107844","article-title":"Severe cutaneous adverse reaction associated with antiseizure medications: diagnosis, management, and prevention","volume":"117","author":"Brandt","year":"2021","journal-title":"Epilepsy Behav"},{"issue":"6","key":"10.1016\/j.yebeh.2021.108517_b0100","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1136\/jnnp.47.6.642","article-title":"Serum anticonvulsant concentrations and the risk of drug induced skin eruptions","volume":"47","author":"Chadwick","year":"1984","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"10.1016\/j.yebeh.2021.108517_b0105","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/j.1528-1167.2007.01041.x","article-title":"Idiosyncratic adverse reactions to antiepileptic drugs","volume":"48","author":"Zaccara","year":"2007","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.yebeh.2021.108517_b0110","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2165\/00002018-199818040-00004","article-title":"Safety review of adult clinical trial experience with lamotrigine","volume":"18","author":"Messenheimer","year":"1998","journal-title":"Drug Saf"},{"issue":"2","key":"10.1016\/j.yebeh.2021.108517_b0115","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1528-1167.2006.00423.x","article-title":"Predictors of lamotrigine-associated rash","volume":"47","author":"Hirsch","year":"2006","journal-title":"Epilepsia"},{"issue":"7","key":"10.1016\/j.yebeh.2021.108517_b0120","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/j.1528-1157.1999.tb00807.x","article-title":"Lamotrigine-associated rash: risk\/benefit considerations in adults and children","volume":"40","author":"Guberman","year":"1999","journal-title":"Epilepsia"},{"issue":"7","key":"10.1016\/j.yebeh.2021.108517_b0125","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1212\/01.WNL.0000156354.20227.F0","article-title":"Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics","volume":"64","author":"Mockenhaupt","year":"2005","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.yebeh.2021.108517_b0130","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/epi.16525","article-title":"Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study","volume":"61","author":"Sperling","year":"2020","journal-title":"Epilepsia"},{"issue":"7","key":"10.1016\/j.yebeh.2021.108517_b0135","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.seizure.2013.03.016","article-title":"Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine","volume":"22","author":"Zaccara","year":"2013","journal-title":"Seizure"},{"issue":"8","key":"10.1016\/j.yebeh.2021.108517_b0140","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1111\/j.1528-1167.2006.00607.x","article-title":"Experimental and clinical evidence for loss of effect (tolerance) during prolonged treatment with antiepileptic drugs","volume":"47","author":"Loscher","year":"2006","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.yebeh.2021.108517_b0145","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/ane.12529","article-title":"Perampanel for focal epilepsy: insights from early clinical experience","volume":"133","author":"Trinka","year":"2016","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2021.108517_b0150","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.eplepsyres.2016.08.001","article-title":"Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting: The FYDATA study","volume":"126","author":"Villanueva","year":"2016","journal-title":"Epilepsy Res"},{"issue":"1","key":"10.1016\/j.yebeh.2021.108517_b0155","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1017\/cjn.2020.174","article-title":"Retention rate and efficacy of perampanel with a slow titration schedule in adults","volume":"48","author":"Basheikh","year":"2021","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.yebeh.2021.108517_b0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2017.10.021","article-title":"Influence of titration schedule and maintenance dose on the tolerability of adjunctive eslicarbazepine acetate: an integrated analysis of three randomized placebo-controlled trials","volume":"139","author":"Krauss","year":"2018","journal-title":"Epilepsy Res"},{"issue":"6","key":"10.1016\/j.yebeh.2021.108517_b0165","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1212\/WNL.46.6.1678","article-title":"Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages","volume":"46","author":"Privitera","year":"1996","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.yebeh.2021.108517_b0170","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1212\/WNL.46.6.1684","article-title":"Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages","volume":"46","author":"Faught","year":"1996","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.yebeh.2021.108517_b0175","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1034\/j.1600-0404.2002.02071.x","article-title":"Low-dose topiramate in adults with treatment-resistant partial-onset seizures","volume":"106","author":"Guberman","year":"2002","journal-title":"Acta Neurol Scand"},{"issue":"2","key":"10.1016\/j.yebeh.2021.108517_b0180","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1345\/aph.10093","article-title":"Topiramate titration and tolerability","volume":"35","author":"Biton","year":"2001","journal-title":"Ann Pharmacother"},{"issue":"10","key":"10.1016\/j.yebeh.2021.108517_b0185","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1111\/bcp.13653","article-title":"New-onset epilepsy in the elderly","volume":"84","author":"Vu","year":"2018","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.yebeh.2021.108517_b0190","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/ane.12218","article-title":"Epilepsy in the elderly: comparing clinical characteristics with younger patients","volume":"129","author":"Stefan","year":"2014","journal-title":"Acta Neurol Scand"},{"issue":"4","key":"10.1016\/j.yebeh.2021.108517_b0195","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.seizure.2010.12.015","article-title":"The safety and efficacy of add-on levetiracetam in elderly patients with focal epilepsy: a one-year observational study","volume":"20","author":"Werhahn","year":"2011","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2021.108517_b0200","doi-asserted-by":"crossref","first-page":"723","DOI":"10.2147\/NDT.S1026","article-title":"Management of epilepsy in the elderly","volume":"3","author":"Poza","year":"2007","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.yebeh.2021.108517_b0205","doi-asserted-by":"crossref","first-page":"107550","DOI":"10.1016\/j.yebeh.2020.107550","article-title":"Trends in oral anticoagulant co-prescription with antiepileptic drugs among adults with epilepsy, 2010\u20132018","volume":"113","author":"Acton","year":"2020","journal-title":"Epilepsy Behav"},{"issue":"13","key":"10.1016\/j.yebeh.2021.108517_b0210","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.017559","article-title":"Direct oral anticoagulant use: a practical guide to common clinical challenges","volume":"9","author":"Chen","year":"2020","journal-title":"JAHA"},{"key":"10.1016\/j.yebeh.2021.108517_b0215","unstructured":"PLAVIX\u00ae (clopidogrel tablets) for oral use [prescribing information]. Bridgewater, NJ: Sanofi-Aventis U.S. LLC; March, 2021."},{"key":"10.1016\/j.yebeh.2021.108517_b0220","unstructured":"COUMADIN\u00ae (warfarin sodium) tablets, for oral use; COUMADIN (warfarin sodium) for injection, for intravenous use [presribing information]. Princeton, NJ: Bristol-Myers Squibb Company October, 2011."},{"key":"10.1016\/j.yebeh.2021.108517_b0225","unstructured":"ELIQUIS\u00ae (apixaban) tablets, for oral use [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; November, 2019."},{"key":"10.1016\/j.yebeh.2021.108517_b0230","unstructured":"XARELTO\u00ae (rivaroxaban) tablets, for oral use [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; November, 2019."},{"issue":"3","key":"10.1016\/j.yebeh.2021.108517_b0235","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1365-2125.2005.02529.x","article-title":"Clinically relevant drug interactions with antiepileptic drugs","volume":"61","author":"Perucca","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.yebeh.2021.108517_b0240","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2174\/157015909788848884","article-title":"Transitional polytherapy: tricks of the trade for monotherapy to monotherapy AED conversions","volume":"7","author":"Garnett","year":"2009","journal-title":"Curr Neuropharmacol"},{"issue":"7","key":"10.1016\/j.yebeh.2021.108517_b0245","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.seizure.2010.05.008","article-title":"on behalf of the Andalusian Epilepsy Society. Antiepileptic treatment in patients with epilepsy and other comorbidities","volume":"19","author":"Ruiz-Gim\u00e9nez","year":"2010","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2021.108517_b0250","doi-asserted-by":"crossref","first-page":"106939","DOI":"10.1016\/j.yebeh.2020.106939","article-title":"Pharmacodynamic interactions of antiepileptic drugs: From bench to clinical practice","volume":"104","author":"Verrotti","year":"2020","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2021.108517_b0255","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.3390\/ph3092956","article-title":"The art of managing conversions between antiepileptic drugs: maximizing patient tolerability and quality of life","volume":"3","author":"St. Louis","year":"2010","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.yebeh.2021.108517_b0260","doi-asserted-by":"crossref","first-page":"106165","DOI":"10.1016\/j.eplepsyres.2019.106165","article-title":"Clinical opinion: earlier employment of polytherapy in sequential pharmacotherapy of epilepsy","volume":"156","author":"Lee","year":"2019","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2021.108517_b0265","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.seizure.2018.11.018","article-title":"Substitution has better efficacy than add-on therapy for patients with focal epilepsy after their first antiepileptic drug treatments fail","volume":"64","author":"Wang","year":"2019","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2021.108517_b0270","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1684\/epd.2014.0650","article-title":"Early add-on treatment vs alternative monotherapy in patients with partial epilepsy","volume":"16","author":"Semah","year":"2014","journal-title":"Epileptic Disord"},{"issue":"1","key":"10.1016\/j.yebeh.2021.108517_b0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2003.09.007","article-title":"Adjunctive therapy versus alternative monotherapy in patients with partial epilepsy failing on a single drug: a multicentre, randomised, pragmatic controlled trial","volume":"57","author":"Beghi","year":"2003","journal-title":"Epilepsy Res"},{"issue":"1","key":"10.1016\/j.yebeh.2021.108517_b0280","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0920-1211(02)00186-9","article-title":"Strategies to prevent overtreatment with antiepileptic drugs in patients with epilepsy","volume":"52","author":"Schmidt","year":"2002","journal-title":"Epilepsy Res"},{"issue":"12","key":"10.1016\/j.yebeh.2021.108517_b0285","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1111\/epi.17092","article-title":"Post hoc analysis of a phase 3, multicenter, open\u2010label study of cenobamate for treatment of uncontrolled focal seizures: Effects of dose adjustments of concomitant antiseizure medications","volume":"62","author":"Rosenfeld","year":"2021","journal-title":"Epilepsia"},{"issue":"11","key":"10.1016\/j.yebeh.2021.108517_b0290","doi-asserted-by":"crossref","first-page":"897","DOI":"10.2165\/00023210-200519110-00001","article-title":"Overtreatment in epilepsy: how it occurs and how it can be avoided","volume":"19","author":"Perucca","year":"2005","journal-title":"CNS Drugs"},{"issue":"12","key":"10.1016\/j.yebeh.2021.108517_b0295","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1111\/j.1528-1167.2011.03325.x","article-title":"Determinants of health-related quality of life in pharmacoresistant epilepsy: results from a large multicenter study of consecutively enrolled patients using validated quantitative assessments","volume":"52","author":"Luoni","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.108517_b0300","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.seizure.2016.12.006","article-title":"Identifying the barriers to antiepileptic drug adherence among adults with epilepsy","volume":"45","author":"O\u2019 Rourke","year":"2017","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2021.108517_b0305","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.seizure.2015.02.025","article-title":"Effect of reduction of antiepileptic drugs in patients with drug-refractory epilepsy","volume":"27","author":"Dash","year":"2015","journal-title":"Seizure"},{"issue":"2","key":"10.1016\/j.yebeh.2021.108517_b0310","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1684\/epd.2017.0907","article-title":"Adjunctive lacosamide for focal epilepsy: an open-label trial evaluating the impact of flexible titration and dosing on safety and seizure outcomes","volume":"19","author":"Baulac","year":"2017","journal-title":"Epileptic Disord"},{"issue":"1","key":"10.1016\/j.yebeh.2021.108517_b0315","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.eplepsyres.2007.06.002","article-title":"The SKATE study: an open-label community-based study of levetiracetam as add-on therapy for adults with uncontrolled partial epilepsy","volume":"76","author":"Steinhoff","year":"2007","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2021.108517_b0320","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.00829","article-title":"Slow titration of cannabidiol add-on in drug-resistant epilepsies can improve safety with maintained efficacy in an open-label study","volume":"11","author":"D'Onofrio","year":"2020","journal-title":"Front Neurol"},{"issue":"3","key":"10.1016\/j.yebeh.2021.108517_b0325","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1345\/aph.1E403","article-title":"Effect of cotherapy reduction on tolerability of epilepsy add-on therapy: a randomized controlled trial","volume":"39","author":"Naritoku","year":"2005","journal-title":"Ann Pharmacother"},{"issue":"5","key":"10.1016\/j.yebeh.2021.108517_b0330","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1345\/aph.1C133","article-title":"Topiramate titration to response: analysis of individualized therapy study (TRAITS)","volume":"37","author":"Dodson","year":"2003","journal-title":"Ann Pharmacother"},{"issue":"4","key":"10.1016\/j.yebeh.2021.108517_b0335","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/ane.12691","article-title":"Lacosamide and sodium channel-blocking antiepileptic drug cross-titration against levetiracetam background therapy","volume":"135","author":"Baulac","year":"2017","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2021.108517_b0340","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.seizure.2020.02.007","article-title":"Predictors of early recurrent seizure after first seizure presentation to an emergency service: a retrospective cohort study","volume":"78","author":"Sathirapanya","year":"2020","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2021.108517_b0345","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1212\/01.wnl.0000473351.32413.7c","article-title":"Evidence-based guideline: management of an unprovoked first seizure in adults: report of the Guideline Development Subcommittee of the American Academy of Neurology and the American Epilepsy Society","volume":"85","author":"Krumholz","year":"2015","journal-title":"Neurology"},{"issue":"18","key":"10.1016\/j.yebeh.2021.108517_b0350","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1212\/WNL.0b013e318254473a","article-title":"Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures","volume":"78","author":"Krauss","year":"2012","journal-title":"Neurology"},{"issue":"Suppl 1","key":"10.1016\/j.yebeh.2021.108517_b0355","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/j.seizure.2004.04.009","article-title":"Review of United States and European clinical trials of zonisamide in the treatment of refractory partial-onset seizures","volume":"13","author":"Faught","year":"2004","journal-title":"Seizure"},{"issue":"22","key":"10.1016\/j.yebeh.2021.108517_b0360","doi-asserted-by":"crossref","first-page":"e2311","DOI":"10.1212\/WNL.0000000000009530","article-title":"Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures","volume":"94","author":"Chung","year":"2020","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.yebeh.2021.108517_b0365","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1474-4422(19)30399-0","article-title":"Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial","volume":"19","author":"Krauss","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2021.108517_b0370","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.yebeh.2015.05.020","article-title":"Perampanel in the treatment of partial seizures: Time to onset and duration of most common adverse events from pooled Phase III and extension studies","volume":"48","author":"Ko","year":"2015","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2021.108517_b0375","doi-asserted-by":"crossref","unstructured":"Klein P, Krauss GL, Aboumatar S, Kamin M. Long-term efficacy and safety of adjunctive cenobamate in patients with uncontrolled focal seizures: open-label extension of a randomized clinical study [poster]. American Epilepsy Society Annual Meeting, December 6\u201310, 2019, Baltimore, MD.","DOI":"10.1212\/WNL.94.15_supplement.1008"},{"key":"10.1016\/j.yebeh.2021.108517_b0380","doi-asserted-by":"crossref","first-page":"107212","DOI":"10.1016\/j.yebeh.2020.107212","article-title":"Time course of drug-related treatment-emergent adverse side effects of brivaracetam","volume":"111","author":"Meador","year":"2020","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2021.108517_b0385","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.yebeh.2016.07.042","article-title":"Correlation between adherence to antiepileptic drugs and quality of life in patients with epilepsy: a longitudinal study","volume":"63","author":"Lin","year":"2016","journal-title":"Epilepsy Behav"},{"issue":"9","key":"10.1016\/j.yebeh.2021.108517_b0390","first-page":"929","article-title":"Antiepileptic drug titration and related health care resource use and costs","volume":"24","author":"Fishman","year":"2018","journal-title":"J Manag Care Spec Pharm"},{"issue":"7","key":"10.1016\/j.yebeh.2021.108517_b0395","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.healthpol.2018.05.012","article-title":"Changing the neurology policy landscape in the United States: Misconceptions and facts about epilepsy","volume":"122","author":"Grabowski","year":"2018","journal-title":"Health Policy"},{"issue":"1","key":"10.1016\/j.yebeh.2021.108517_b0400","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s40801-020-00216-5","article-title":"Association between adverse events and discontinuation of antiepileptic drugs among drug-na\u00efve adults with epilepsy","volume":"8","author":"Peasah","year":"2021","journal-title":"Drugs Real World Outcomes"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505021007782?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505021007782?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:45:31Z","timestamp":1761504331000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505021007782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":80,"alternative-id":["S1525505021007782"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2021.108517","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The importance of drug titration in the management of patients with epilepsy","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2021.108517","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108517"}}